- Construction has begun on a new diagnostic manufacturing site, which will have capacity to produce up to 40 million tests per year
- The first products to be manufactured will be rapid COVID-19 diagnostic tests
- The new facility is a legally separate social enterprise with a mission to deliver diagnostics at a fair price to the national and international markets
- It will also become a training facility for partners in low-income countries and regions currently poorly served by diagnostics provision
Bedfordshire, UK, 24 APRIL 2020: Mologic Ltd, a leading developer of lateral flow and rapid diagnostic technologies, disclosed today that work is well underway on a new diagnostic manufacturing facility adjacent to the firm’s current laboratory in Bedfordshire, UK.
The facility has been incorporated as an independent, sustainable social enterprise under the name of Global Access Diagnostics, with a commitment to deliver diagnostics at a fair price to both national and international markets.
The expansion is supported by the Foundation for Innovative New Diagnostics (FIND), a global non-profit dedicated to diagnostics for global health. It follows Mologic’s development of consistently high quality, independently verified diagnostic products, including ELISA laboratory tests and rapid diagnostic tests for diseases such as COVID-19 and Ebola.
The first products to be manufactured in the facility will be rapid diagnostic tests for COVID-19, as part of Mologic’s commitment to support the global pandemic response.
The new facility will be operational within eight weeks, enabling the company to produce up to 40 million tests per year, scaling from the existing manufacturing capability.
Global Access Diagnostics will also become a training facility for partners in low-income countries and regions that are currently poorly served by diagnostics provision. The facility will also look to support the establishment of manufacturing partnerships within low-income countries dedicated to serving the specific diagnostic needs of their people and regions.
This work to improve access to high quality diagnostics in countries with less robust health systems builds on Mologic’s existing partnership with the Institut Pasteur de Dakar in Senegal, who have started to manufacture the Dengue test at diaTROPiX, a flagship manufacturing facility in Senegal, ahead of the COVID19 diagnostic in early May.
Mark Davis, CEO, Mologic: “This new facility is an exciting development in Mologic’s efforts to improve access to quality diagnostics in low-income setting and to support the global pandemic response in the UK, Africa and throughout the world. We are thankful to the many donors and investors who believe in our mission to make diagnostics affordable and accessible for all.”
Catharina Boehme, CEO, FIND: “FIND has a longstanding partnership with Mologic, working together to fill diagnostic gaps for emerging threats including dengue and yellow fever, and setting up manufacturing capacity in Africa. It is a logical step for us now to strengthen manufacturing capacity for tests that are urgently needed to combat the COVID-19 threat today, and critical for pandemic preparedness and global health security in the future.”
Mark Radford, Executive Director, Global Access Diagnostics: “COVID-19 is a reminder that viruses respect no boundaries and that investing in the capacity of all countries to strengthen their disease surveillance and containment is actually an investment in health security for us all. Mologic and Global Access Diagnostics are at the forefront of making access to testing a reality in some of the world’s poorest countries, through our collaboration with partners in Africa, including Institut Pasteur de Dakar.”